COMRADE: Olaparib plus radium-223 improves rPFS in mCRPC
In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 alone in patients with metastatic castration-resistant …